false
0001494891
0001494891
2026-06-02
2026-06-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
____________________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 2, 2026
SENSUS
HEALTHCARE, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-37714 |
|
27-1647271 |
| (State
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer Identification No.) |
851
Broken Sound Pkwy., NW # 215, Boca Raton, Florida |
|
33487 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant's
telephone number, including area code: (561) 922-5808
_________________________________________________
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
| Common Stock, par value $0.01 per share |
SRTS |
Nasdaq Stock Market, LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SENSUS
HEALTHCARE, INC.
FORM
8-K
CURRENT
REPORT
| Item 1.01 | Entry
into a Material Definitive Agreement. |
On
June 2, 2026, Sensus Healthcare, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with
City National Bank of Florida (“CNB”) pursuant to which CNB has made available to the Company a revolving credit facility
providing for maximum borrowings of $15,000,000 (the “Loan”), which is evidenced by a Revolving Promissory Note, dated June
2, 2026 (the “Note”), made by the Company in favor of CNB. Pursuant to the terms of the Note, advances made under the Loan
bear interest at the Secured Overnight Financing Rate plus 3% per annum and have a maturity date of June 5, 2027 unless extended by mutual
agreement of the Company and CNB. Pursuant to a Pledged Collateral and Restricted Account Agreement, dated June 2, 2026 (the “Pledged
Collateral Agreement”), between the Company and CNB, the Loan is secured by cash collateral in the amount of $2,230,000, and pursuant
to a Security Agreement, dated June 2, 2026 (the “Security Agreement”), between the Company and CNB, the Loan is secured
by a security interest in all of the Company’s assets (the “Collateral”).
Under
the Loan Agreement, the Company must obtain CNB’s prior written consent in order to take any of the following actions: (a) sell
or transfer any of the Company’s assets outside the ordinary course of its business; (b) incur, create, assume, or permit to exist
any other indebtedness (subject to certain exceptions); (c) encumber any of the Company’s assets with any liens other than liens
in favor of CNB and certain other permitted liens, or (d) remove the Company’s current Chief Executive Officer, President or Chief
Financial Officer. The Loan Agreement contains a financial covenant requiring that the Company maintain a minimum debt service coverage
ratio of 1.50. The Loan Agreement also contains customary representations and warranties and customary events of default, upon the occurrence
of which, after any applicable grace period, CNB would have the ability to accelerate all outstanding advances, terminate the Loan, and
exercise remedies with respect to the Collateral.
This
description of the Loan Agreement, Note, Pledged Collateral Agreement, and Security Agreement is qualified in its entirety by reference
to the Loan Agreement, Note, Pledged Collateral Agreement, and Security Agreement, which are attached as Exhibits 10.1, 10.2, 10.3, and
10.4, respectively.
As
previously reported, the Company’s previous revolving credit facility, made available to the Company by Fifth Third Bank, N.A.,
as successor to Comerica Bank, has been terminated.
| Item 9.01 | Financial
Statements and Exhibits |
(d)
Exhibits.
| |
|
Exhibit
Number |
Description |
| 10.1 |
Loan Agreement, dated as of June 2, 2026, by and between the Company and CNB |
| 10.2 |
Revolving Promissory Note, dated as of June 2, 2026, made by the Company in favor of CNB |
| 10.3 |
Pledged Collateral and Restricted Account Agreement, dated as of June 2, 2026, by and between the Company and CNB |
| 10.4 |
Security Agreement, dated as of June 2, 2026, by and between the Company and CNB |
| 104 |
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
SENSUS HEALTHCARE, INC. |
| |
|
|
| |
|
|
| Date: June
5, 2026 |
By: |
/s/ Javier Rampolla |
| |
|
Javier Rampolla |
| |
|
Chief Financial Officer |
| |
|
|
